<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27320846</article-id><article-id pub-id-type="pmc">4913255</article-id><article-id pub-id-type="pii">srep28282</article-id><article-id pub-id-type="doi">10.1038/srep28282</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: A double-blind randomised clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Borges</surname><given-names>Cynthia M.</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Papadimitriou</surname><given-names>Alexandros</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Duarte</surname><given-names>Diego A.</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lopes de Faria</surname><given-names>Jacqueline M.</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lopes de Faria</surname><given-names>José B.</given-names></name><xref ref-type="corresp" rid="c1">a</xref><xref ref-type="aff" rid="a1">1</xref></contrib><aff id="a1"><label>1</label><institution>Renal Pathophysiology Laboratory, Investigation on Diabetes Complications, Nephrology Unit, Faculty of Medical Sciences (FCM), State University of Campinas (UNICAMP)</institution>, Campinas, São Paulo, <country>Brazil</country></aff></contrib-group><author-notes><corresp id="c1"><label>a</label><email>jblfaria@fcm.unicamp.br</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>06</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>6</volume><elocation-id>28282</elocation-id><history><date date-type="received"><day>28</day><month>01</month><year>2016</year></date><date date-type="accepted"><day>31</day><month>05</month><year>2016</year></date></history><permissions><copyright-statement>Copyright © 2016, Macmillan Publishers Limited</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Macmillan Publishers Limited</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license></permissions><abstract><p><offsets xml_i="3551" xml_f="4379" txt_i="11" txt_f="836">Prior research has shown that in experimental diabetes mellitus, green tea reduces albuminuria by decreasing podocyte apoptosis through activation of the WNT pathway. We investigated the effect of green tea polyphenols (GTP) on residual albuminuria of diabetic subjects with nephropathy. We conducted a randomised, double-blind study in 42 diabetic subjects with a urinary albumin-creatinine ratio (UACR) &gt;30 mg/g, despite administration of the maximum recommended dose of renin-angiotensin (RAS) inhibition. Patients were randomly assigned to two equal groups to receive either GTP (containing 800 mg of epigallocatechin gallate, 17 with type 2 diabetes and 4 with type 1 diabetes) or placebo (21 with type 2 diabetes) for 12 weeks. Treatment with GTP reduced UACR by 41%, while the placebo group saw a 2% increase in UACR (</offsets><italic><offsets xml_i="4387" xml_f="4388" txt_i="836" txt_f="837">p</offsets></italic><offsets xml_i="4397" xml_f="4428" txt_i="837" txt_f="868"> = 0.019). Podocyte apoptosis (</offsets><italic><offsets xml_i="4436" xml_f="4437" txt_i="868" txt_f="869">p</offsets></italic><offsets xml_i="4446" xml_f="4460" txt_i="869" txt_f="883"> = 0.001) and </offsets><italic><offsets xml_i="4468" xml_f="4476" txt_i="883" txt_f="891">in vitro</offsets></italic><offsets xml_i="4485" xml_f="4508" txt_i="891" txt_f="914"> albumin permeability (</offsets><italic><offsets xml_i="4516" xml_f="4517" txt_i="914" txt_f="915">p</offsets></italic><offsets xml_i="4526" xml_f="4914" txt_i="915" txt_f="1300"> &lt; 0.001) were higher in immortalized human podocytes exposed to plasma from diabetic subjects compared to podocytes treated with plasma from normal individuals. In conclusion, GTP administration reduces albuminuria in diabetic patients receiving the maximum recommended dose of RAS. Reduction in podocyte apoptosis by activation of the WNT pathway may have contributed to this effect.</offsets></p></abstract></article-meta></front><body><p><offsets xml_i="4961" xml_f="5295" txt_i="1308" txt_f="1642">Multifactorial treatment by means of blood glucose and blood pressure control, including maximum doses of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), as well as administration of lipid lowering drugs, is an efficient, though insufficient, approach to treatment for diabetic nephropathy (DN)</offsets><xref ref-type="bibr" rid="b1"><offsets xml_i="5326" xml_f="5327" txt_i="1642" txt_f="1643">1</offsets></xref><offsets xml_i="5334" xml_f="5476" txt_i="1643" txt_f="1785">. Despite the availability of so many effective interventions, DN remains the main cause of end-stage renal disease in most parts of the world</offsets><xref ref-type="bibr" rid="b2"><offsets xml_i="5507" xml_f="5508" txt_i="1785" txt_f="1786">2</offsets></xref><offsets xml_i="5515" xml_f="5516" txt_i="1786" txt_f="1787">.</offsets></p><p><offsets xml_i="5523" xml_f="5757" txt_i="1788" txt_f="2022">In patients with DN, post hoc analyses of trial outcomes have demonstrated a robust relationship between the magnitude of albuminuria reduction and the slowing of chronic kidney disease (CKD) and reduced rates of cardiovascular events</offsets><xref ref-type="bibr" rid="b3"><offsets xml_i="5788" xml_f="5789" txt_i="2022" txt_f="2023">3</offsets></xref><xref ref-type="bibr" rid="b4"><offsets xml_i="5827" xml_f="5828" txt_i="2023" txt_f="2024">4</offsets></xref><xref ref-type="bibr" rid="b5"><offsets xml_i="5866" xml_f="5867" txt_i="2024" txt_f="2025">5</offsets></xref><xref ref-type="bibr" rid="b6"><offsets xml_i="5905" xml_f="5906" txt_i="2025" txt_f="2026">6</offsets></xref><xref ref-type="bibr" rid="b7"><offsets xml_i="5944" xml_f="5945" txt_i="2026" txt_f="2027">7</offsets></xref><xref ref-type="bibr" rid="b8"><offsets xml_i="5983" xml_f="5984" txt_i="2027" txt_f="2028">8</offsets></xref><offsets xml_i="5991" xml_f="6118" txt_i="2028" txt_f="2155">. In addition, the high residual risk in diabetic nephropathy is directly related to the residual albuminuria in these patients</offsets><xref ref-type="bibr" rid="b9"><offsets xml_i="6149" xml_f="6150" txt_i="2155" txt_f="2156">9</offsets></xref><offsets xml_i="6157" xml_f="6324" txt_i="2156" txt_f="2323">. Therefore, new treatment options must be added to the current armamentarium, especially drugs that can lower residual risk factors without increasing adverse events.</offsets></p><p><offsets xml_i="6331" xml_f="6374" txt_i="2324" txt_f="2367">Preclinical studies in diabetic nephropathy</offsets><xref ref-type="bibr" rid="b10"><offsets xml_i="6406" xml_f="6408" txt_i="2367" txt_f="2369">10</offsets></xref><xref ref-type="bibr" rid="b11"><offsets xml_i="6447" xml_f="6449" txt_i="2369" txt_f="2371">11</offsets></xref><xref ref-type="bibr" rid="b12"><offsets xml_i="6488" xml_f="6490" txt_i="2371" txt_f="2373">12</offsets></xref><offsets xml_i="6497" xml_f="6543" txt_i="2373" txt_f="2419"> and in rapidly progressive glomerulonephritis</offsets><xref ref-type="bibr" rid="b13"><offsets xml_i="6575" xml_f="6577" txt_i="2419" txt_f="2421">13</offsets></xref><offsets xml_i="6584" xml_f="6834" txt_i="2421" txt_f="2671"> have demonstrated that green tea (GT) is able to reduce albuminuria and other markers of renal damage. In experimental DN studies, GT was able to reduce oxidative stress markers by inhibiting NOX4, as well as nitric oxidase synthase (NOS) uncoupling</offsets><xref ref-type="bibr" rid="b10"><offsets xml_i="6866" xml_f="6868" txt_i="2671" txt_f="2673">10</offsets></xref><xref ref-type="bibr" rid="b11"><offsets xml_i="6907" xml_f="6909" txt_i="2673" txt_f="2675">11</offsets></xref><offsets xml_i="6916" xml_f="7060" txt_i="2675" txt_f="2819">. In addition, we recently demonstrated that under experimental diabetic conditions, GT reduces podocyte apoptosis by activating the WNT pathway</offsets><xref ref-type="bibr" rid="b12"><offsets xml_i="7092" xml_f="7094" txt_i="2819" txt_f="2821">12</offsets></xref><offsets xml_i="7101" xml_f="7427" txt_i="2821" txt_f="3147">. Interestingly, GT was not able to reduce podocyte apoptosis when podocytes exposed to high glucose were treated with dickkopf 1 (DKK-1). DKK-1 is a blocker of low-density lipoprotein receptor-related protein 6 (LRP6), a receptor of the WNT pathway that is involved in podocyte death under conditions of high glucose exposure</offsets><xref ref-type="bibr" rid="b14"><offsets xml_i="7459" xml_f="7461" txt_i="3147" txt_f="3149">14</offsets></xref><offsets xml_i="7468" xml_f="7588" txt_i="3149" txt_f="3269">. We concluded that GT could ameliorate albuminuria by reducing podocyte apoptosis through activation of the WNT pathway</offsets><xref ref-type="bibr" rid="b12"><offsets xml_i="7620" xml_f="7622" txt_i="3269" txt_f="3271">12</offsets></xref><offsets xml_i="7629" xml_f="7630" txt_i="3271" txt_f="3272">.</offsets></p><p><offsets xml_i="7637" xml_f="7831" txt_i="3273" txt_f="3467">A recent meta-analysis of studies in human subjects concluded that moderate consumption of GT reduces the risk of cardiovascular events and stroke by enhancing endothelial-dependent vasodilation</offsets><xref ref-type="bibr" rid="b15"><offsets xml_i="7863" xml_f="7865" txt_i="3467" txt_f="3469">15</offsets></xref><offsets xml_i="7872" xml_f="8098" txt_i="3469" txt_f="3695">. In addition, the use of the main GT catechin, epigallocatechin gallate (EGCG), administered in doses of up to 800 mg daily, is safe for healthy postmenopausal women and reduces their LDL-cholesterol and plasma insulin levels</offsets><xref ref-type="bibr" rid="b16"><offsets xml_i="8130" xml_f="8132" txt_i="3695" txt_f="3697">16</offsets></xref><offsets xml_i="8139" xml_f="8250" txt_i="3697" txt_f="3808">. To our knowledge, no study in humans has evaluated the potential efficacy of GT in treating patients with DN.</offsets></p><p><offsets xml_i="8257" xml_f="8592" txt_i="3809" txt_f="4144">The aim of this study was to investigate whether green tea polyphenols (GTP) can reduce residual albuminuria in diabetic subjects receiving the maximum recommended dose of ACE inhibitors and/or ARBs and to test the hypothesis that GTP exerts its antiproteinuric effect via reduction of podocyte apoptosis by activating the WNT pathway.</offsets></p><sec disp-level="1"><title><offsets xml_i="8623" xml_f="8630" txt_i="4145" txt_f="4152">Results</offsets></title><p><offsets xml_i="8641" xml_f="8783" txt_i="4153" txt_f="4295">The screening phase of this trial started in November 2013; the treatment phase was completed by December 2014. As shown in the flow diagram (</offsets><xref ref-type="fig" rid="f1"><offsets xml_i="8813" xml_f="8819" txt_i="4295" txt_f="4301">Fig. 1</offsets></xref><offsets xml_i="8826" xml_f="8945" txt_i="4301" txt_f="4420">), 47 patients were enrolled in the study and randomly assigned to one of two groups to receive either GTP or placebo (</offsets><xref ref-type="table" rid="t1"><offsets xml_i="8977" xml_f="8984" txt_i="4420" txt_f="4427">Table 1</offsets></xref><offsets xml_i="8991" xml_f="9291" txt_i="4427" txt_f="4727">). Two patients in the GTP group and three patients in the placebo group were ultimately excluded from final analysis of the study due to withdrawal of their consent and unavailability of final laboratory data. Eventually, 21 patients in each group completed the 12-week treatment phase of the trial.</offsets></p><sec disp-level="2"><title><offsets xml_i="9322" xml_f="9338" txt_i="4728" txt_f="4744">Primary endpoint</offsets></title><p><offsets xml_i="9349" xml_f="9964" txt_i="4745" txt_f="5360">The same regime reported at baseline for RAS inhibition was maintained in all 42 patients who completed the study. Patients receiving GTP had a median (range) UACR of 210 mg/g (39–1267) at baseline, which was reduced to 133 mg/g (10–1812). Patients receiving placebo, on the other hand, experienced an increase in UACR, from 427 mg/g (77–4051) at baseline to 452 mg/g (43–4802) by week 12. After 12 weeks of treatment, GTP had reduced the geometric mean of % change from baseline (95% confidence interval [CI]) of UACR by 41% (−0.64/0.96), while in the placebo group a tiny increase of 2% (−0.13/0.45) was noticed (</offsets><italic><offsets xml_i="9972" xml_f="9973" txt_i="5360" txt_f="5361">p</offsets></italic><offsets xml_i="9982" xml_f="9993" txt_i="5361" txt_f="5372"> = 0.019) (</offsets><xref ref-type="fig" rid="f2"><offsets xml_i="10023" xml_f="10029" txt_i="5372" txt_f="5378">Fig. 2</offsets></xref><offsets xml_i="10036" xml_f="10234" txt_i="5378" txt_f="5576">). The beneficial effect of GTP on albuminuria was maintained even when we included only patients with diabetes mellitus (DM) type 2 in the analyses, resulting in a 37% reduction vs. a 4% increase (</offsets><italic><offsets xml_i="10242" xml_f="10243" txt_i="5576" txt_f="5577">p</offsets></italic><offsets xml_i="10252" xml_f="10468" txt_i="5577" txt_f="5793"> = 0.03) for the GTP and placebo groups, respectively. Notably, 19% of patients in the GTP group and none in the placebo group moved from macroalbuminuria or microalbuminuria to microalbuminuria or normoalbuminuria (</offsets><italic><offsets xml_i="10476" xml_f="10477" txt_i="5793" txt_f="5794">p</offsets></italic><offsets xml_i="10486" xml_f="10495" txt_i="5794" txt_f="5803"> = 0.03).</offsets></p></sec><sec disp-level="2"><title><offsets xml_i="10532" xml_f="10551" txt_i="5805" txt_f="5824">Secondary endpoints</offsets></title><p><offsets xml_i="10562" xml_f="10836" txt_i="5825" txt_f="6099">Median values for changes in 24-hour systolic and diastolic blood pressures, body mass index (BMI), glycated haemoglobin (HbA1c), estimated glomerular filtration rate (eGFR) values, and serum C-reactive protein (CRP) were not significantly different between the two groups (</offsets><xref ref-type="table" rid="t2"><offsets xml_i="10868" xml_f="10875" txt_i="6099" txt_f="6106">Table 2</offsets></xref><offsets xml_i="10882" xml_f="10988" txt_i="6106" txt_f="6212">). However, the addition of GTP to the existing treatment regimen significantly reduced mean serum DKK-1 (</offsets><italic><offsets xml_i="10996" xml_f="10997" txt_i="6212" txt_f="6213">p</offsets></italic><offsets xml_i="11006" xml_f="11056" txt_i="6213" txt_f="6263"> = 0.004) and tumor necrosis factor alpha (TNF-α; </offsets><italic><offsets xml_i="11064" xml_f="11065" txt_i="6263" txt_f="6264">p</offsets></italic><offsets xml_i="11074" xml_f="11152" txt_i="6264" txt_f="6342"> = 0.003) with no significant change in urinary 8-isoprostane concentrations (</offsets><xref ref-type="table" rid="t3"><offsets xml_i="11184" xml_f="11191" txt_i="6342" txt_f="6349">Table 3</offsets></xref><offsets xml_i="11198" xml_f="11200" txt_i="6349" txt_f="6351">).</offsets></p></sec><sec disp-level="2"><title><offsets xml_i="11237" xml_f="11251" txt_i="6353" txt_f="6367">Adverse events</offsets></title><p><offsets xml_i="11262" xml_f="11484" txt_i="6368" txt_f="6590">No patients withdrew from the study because of adverse events associated with treatment. One patient developed diarrhea and another had dyspepsia after GTP treatment. One patient reported dizziness after placebo treatment.</offsets></p></sec><sec disp-level="2"><title><italic><offsets xml_i="11529" xml_f="11537" txt_i="6592" txt_f="6600">In vitro</offsets></italic><offsets xml_i="11546" xml_f="11554" txt_i="6600" txt_f="6608"> studies</offsets></title><sec disp-level="3"><title><offsets xml_i="11589" xml_f="11713" txt_i="6609" txt_f="6733">Plasma from diabetic patients increased albumin permeability and markers of apoptosis in immortalized human podocytes (iHPs)</offsets></title><p><offsets xml_i="11724" xml_f="11821" txt_i="6734" txt_f="6831">Treatment of iHPs with plasma from diabetic subjects resulted in increased albumin permeability (</offsets><italic><offsets xml_i="11829" xml_f="11830" txt_i="6831" txt_f="6832">p</offsets></italic><offsets xml_i="11839" xml_f="11852" txt_i="6832" txt_f="6842"> &lt; 0.001, </offsets><xref ref-type="fig" rid="f3"><offsets xml_i="11882" xml_f="11888" txt_i="6842" txt_f="6848">Fig. 3</offsets></xref><offsets xml_i="11895" xml_f="11943" txt_i="6848" txt_f="6896">) and markers of apoptosis (caspase 3 activity, </offsets><italic><offsets xml_i="11951" xml_f="11952" txt_i="6896" txt_f="6897">p</offsets></italic><offsets xml_i="11961" xml_f="12047" txt_i="6897" txt_f="6980"> &lt; 0.001 and terminal deoxynucleotidyl transferase dUTP nick end labeling [TUNEL], </offsets><italic><offsets xml_i="12055" xml_f="12056" txt_i="6980" txt_f="6981">p</offsets></italic><offsets xml_i="12065" xml_f="12076" txt_i="6981" txt_f="6992"> = 0.001) (</offsets><xref ref-type="fig" rid="f4"><offsets xml_i="12106" xml_f="12112" txt_i="6992" txt_f="6998">Fig. 4</offsets></xref><offsets xml_i="12119" xml_f="12399" txt_i="6998" txt_f="7278">) as compared to podocytes treated with plasma from control subjects. Notably, we did not observe differences in these same parameters when we compared podocytes treated with plasma from control subjects with podocytes treated with plasma from diabetic patients who received GTP (</offsets><xref ref-type="fig" rid="f3"><offsets xml_i="12429" xml_f="12435" txt_i="7278" txt_f="7284">Figs 3</offsets></xref><offsets xml_i="12442" xml_f="12447" txt_i="7284" txt_f="7289"> and </offsets><xref ref-type="fig" rid="f4"><offsets xml_i="12477" xml_f="12478" txt_i="7289" txt_f="7290">4</offsets></xref><offsets xml_i="12485" xml_f="12487" txt_i="7290" txt_f="7292">).</offsets></p></sec><sec disp-level="3"><title><offsets xml_i="12524" xml_f="12677" txt_i="7294" txt_f="7447">Addition of DKK-1 to plasma from diabetic subjects who received GTP reversed the protective effect on albumin permeability and podocyte apoptosis markers</offsets></title><p><offsets xml_i="12688" xml_f="12986" txt_i="7448" txt_f="7746">To test the possible contribution of WNT pathway activation to increased albumin permeability and podocyte apoptosis markers, we treated plasma from diabetic patients who received GTP with DKK-1, a WNT inhibitor. Interestingly, the protective effect of GTP was eliminated by the addition of DKK-1 (</offsets><xref ref-type="fig" rid="f3"><offsets xml_i="13016" xml_f="13022" txt_i="7746" txt_f="7752">Figs 3</offsets></xref><offsets xml_i="13029" xml_f="13034" txt_i="7752" txt_f="7757"> and </offsets><xref ref-type="fig" rid="f4"><offsets xml_i="13064" xml_f="13065" txt_i="7757" txt_f="7758">4</offsets></xref><offsets xml_i="13072" xml_f="13074" txt_i="7758" txt_f="7760">).</offsets></p></sec><sec disp-level="3"><title><offsets xml_i="13111" xml_f="13221" txt_i="7762" txt_f="7872">Addition of EGCG to plasma of diabetic subjects reduced albumin permeability and markers of podocyte apoptosis</offsets></title><p><offsets xml_i="13232" xml_f="13345" txt_i="7873" txt_f="7986">Addition of EGCG (436 nM) to plasma from diabetic subjects who did not receive GTP reduced albumin permeability (</offsets><italic><offsets xml_i="13353" xml_f="13354" txt_i="7986" txt_f="7987">p</offsets></italic><offsets xml_i="13363" xml_f="13407" txt_i="7987" txt_f="8031"> = 0.01) and markers of podocyte apoptosis (</offsets><italic><offsets xml_i="13415" xml_f="13416" txt_i="8031" txt_f="8032">p</offsets></italic><offsets xml_i="13425" xml_f="13513" txt_i="8032" txt_f="8120"> = 0.007) to the levels observed in podocytes treated with plasma from normal subjects (</offsets><xref ref-type="fig" rid="f3"><offsets xml_i="13543" xml_f="13549" txt_i="8120" txt_f="8126">Figs 3</offsets></xref><offsets xml_i="13556" xml_f="13561" txt_i="8126" txt_f="8131"> and </offsets><xref ref-type="fig" rid="f4"><offsets xml_i="13591" xml_f="13592" txt_i="8131" txt_f="8132">4</offsets></xref><offsets xml_i="13599" xml_f="13601" txt_i="8132" txt_f="8134">).</offsets></p></sec></sec></sec><sec disp-level="1"><title><offsets xml_i="13650" xml_f="13660" txt_i="8138" txt_f="8148">Discussion</offsets></title><p><offsets xml_i="13671" xml_f="14233" txt_i="8149" txt_f="8711">To our knowledge, this study is the first to demonstrate the efficacy and safety of adding GTP to maximum doses of ACE inhibitors and/or ARBs in order to reduce residual albuminuria in patients with diabetic nephropathy. Improvement in glomerular barrier selectivity due to reduction in podocyte apoptosis as a result of decreased plasma DKK-1 and WNT pathway activation may be the possible mechanism behind this observed efficacy. It is also possible that inhibition of inflammatory mediators (such as TNF-α) may have contributed to the beneficial effect of GTP</offsets><xref ref-type="bibr" rid="b17"><offsets xml_i="14265" xml_f="14267" txt_i="8711" txt_f="8713">17</offsets></xref><offsets xml_i="14274" xml_f="14529" txt_i="8713" txt_f="8968">. The findings of the current study confirm in a clinical setting our preclinical study that suggested the ability of green tea to reduce albuminuria in diabetic nephropathy, probably by diminishing podocyte apoptosis through activation of the WNT pathway</offsets><xref ref-type="bibr" rid="b12"><offsets xml_i="14561" xml_f="14563" txt_i="8968" txt_f="8970">12</offsets></xref><offsets xml_i="14570" xml_f="14571" txt_i="8970" txt_f="8971">.</offsets></p><p><offsets xml_i="14578" xml_f="14722" txt_i="8972" txt_f="9116">Previous studies have demonstrated that plasma DKK-1 is indeed elevated in type 2 diabetic patients in comparison to plasma from normal subjects</offsets><xref ref-type="bibr" rid="b18"><offsets xml_i="14754" xml_f="14756" txt_i="9116" txt_f="9118">18</offsets></xref><xref ref-type="bibr" rid="b19"><offsets xml_i="14795" xml_f="14797" txt_i="9118" txt_f="9120">19</offsets></xref><offsets xml_i="14804" xml_f="14927" txt_i="9120" txt_f="9243">. In addition, elevated plasma concentrations of DKK-1 are associated with macrovascular disease in patients with type 2 DM</offsets><xref ref-type="bibr" rid="b18"><offsets xml_i="14959" xml_f="14961" txt_i="9243" txt_f="9245">18</offsets></xref><offsets xml_i="14968" xml_f="15028" txt_i="9245" txt_f="9305">, as well as endothelial dysfunction and platelet activation</offsets><xref ref-type="bibr" rid="b19"><offsets xml_i="15060" xml_f="15062" txt_i="9305" txt_f="9307">19</offsets></xref><offsets xml_i="15069" xml_f="15193" txt_i="9307" txt_f="9431">. Interestingly, plasma concentrations of DKK-1 can be reduced with improved glycemic control and low-dose aspirin treatment</offsets><xref ref-type="bibr" rid="b19"><offsets xml_i="15225" xml_f="15227" txt_i="9431" txt_f="9433">19</offsets></xref><offsets xml_i="15234" xml_f="15389" txt_i="9433" txt_f="9588">. In the present study, we demonstrated that GTP reduces plasma concentrations of DKK-1 independently of its effect on glycemic and blood pressure control.</offsets></p><p><offsets xml_i="15396" xml_f="15631" txt_i="9589" txt_f="9824">DKK-1 is a major regulator of the WNT pathway, a group of highly conserved secreted mediators that regulate a wide range of cellular processes, such as proliferation and differentiation, survival, cell fate determination, and migration</offsets><xref ref-type="bibr" rid="b20"><offsets xml_i="15663" xml_f="15665" txt_i="9824" txt_f="9826">20</offsets></xref><offsets xml_i="15672" xml_f="15983" txt_i="9826" txt_f="10137">. Scant but controversial evidence exists for the role of the WNT pathway in podocyte apoptosis. It has been suggested that in experimental DM, high glucose may activate the WNT pathway through stimulation of the transient receptor potential channel 6 (TRPC6), which eventually contributes to podocyte apoptosis</offsets><xref ref-type="bibr" rid="b21"><offsets xml_i="16015" xml_f="16017" txt_i="10137" txt_f="10139">21</offsets></xref><offsets xml_i="16024" xml_f="16177" txt_i="10139" txt_f="10292">. On the contrary, Kato and colleagues have suggested that down-regulation of the WNT pathway in podocytes might in fact enhance apoptosis susceptibility</offsets><xref ref-type="bibr" rid="b14"><offsets xml_i="16209" xml_f="16211" txt_i="10292" txt_f="10294">14</offsets></xref><offsets xml_i="16218" xml_f="16312" txt_i="10294" txt_f="10388">. This last suggestion was confirmed by our recent observations, wherein we demonstrated—both </offsets><italic><offsets xml_i="16320" xml_f="16327" txt_i="10388" txt_f="10395">in vivo</offsets></italic><offsets xml_i="16336" xml_f="16341" txt_i="10395" txt_f="10400"> and </offsets><italic><offsets xml_i="16349" xml_f="16357" txt_i="10400" txt_f="10408">in vitro</offsets></italic><offsets xml_i="16366" xml_f="16562" txt_i="10408" txt_f="10604">—that high glucose or blockage of the WNT receptor, LRP6, with DKK-1 or silencing RNA increases glycogen synthase kinase 3 beta (GSK3β), its interaction with p53, and ultimately podocyte apoptosis</offsets><xref ref-type="bibr" rid="b12"><offsets xml_i="16594" xml_f="16596" txt_i="10604" txt_f="10606">12</offsets></xref><offsets xml_i="16603" xml_f="16648" txt_i="10606" txt_f="10651">. GSK3β is involved in WNT pathway regulation</offsets><xref ref-type="bibr" rid="b22"><offsets xml_i="16680" xml_f="16682" txt_i="10651" txt_f="10653">22</offsets></xref><offsets xml_i="16689" xml_f="16851" txt_i="10653" txt_f="10815">. Its activation promotes proteasomal degradation of the transcription factor β-catenin and inhibits cytoplasmic accumulation and subsequent nuclear translocation</offsets><xref ref-type="bibr" rid="b22"><offsets xml_i="16883" xml_f="16885" txt_i="10815" txt_f="10817">22</offsets></xref><offsets xml_i="16892" xml_f="16955" txt_i="10817" txt_f="10880">. Therefore, WNT target genes are not transcripted by β-catenin</offsets><xref ref-type="bibr" rid="b22"><offsets xml_i="16987" xml_f="16989" txt_i="10880" txt_f="10882">22</offsets></xref><offsets xml_i="16996" xml_f="17118" txt_i="10882" txt_f="11004">. We are unaware of any study that has investigated the role of DKK-1/WNT pathway in podocyte apoptosis in human subjects.</offsets></p><p><offsets xml_i="17125" xml_f="17279" txt_i="11005" txt_f="11159">Previous research has shown that in cultured podocytes, plasma from diabetic subjects with nephropathy induces apoptosis, as assessed by cleaved caspase 3</offsets><xref ref-type="bibr" rid="b23"><offsets xml_i="17311" xml_f="17313" txt_i="11159" txt_f="11161">23</offsets></xref><offsets xml_i="17320" xml_f="17474" txt_i="11161" txt_f="11315">. Herein, we confirmed that plasma from diabetic patients with nephropathy promotes podocyte apoptosis, as assessed by cleaved caspase 3 and TUNEL assay (</offsets><xref ref-type="fig" rid="f4"><offsets xml_i="17504" xml_f="17510" txt_i="11315" txt_f="11321">Fig. 4</offsets></xref><offsets xml_i="17517" xml_f="17754" txt_i="11321" txt_f="11558">), likely due to an increased concentration of plasma DKK-1. This suggestion is supported by our observation that the protective effect of plasma from diabetic patients who received GTP was lost when we treated the podocytes with DKK-1 (</offsets><xref ref-type="fig" rid="f4"><offsets xml_i="17784" xml_f="17790" txt_i="11558" txt_f="11564">Fig. 4</offsets></xref><offsets xml_i="17797" xml_f="17841" txt_i="11564" txt_f="11608">). Similar results were also observed in an </offsets><italic><offsets xml_i="17849" xml_f="17857" txt_i="11608" txt_f="11616">in vitro</offsets></italic><offsets xml_i="17866" xml_f="17898" txt_i="11616" txt_f="11648"> model of albumin permeability (</offsets><xref ref-type="fig" rid="f3"><offsets xml_i="17928" xml_f="17934" txt_i="11648" txt_f="11654">Fig. 3</offsets></xref><offsets xml_i="17941" xml_f="17943" txt_i="11654" txt_f="11656">).</offsets></p><p><offsets xml_i="17950" xml_f="18242" txt_i="11657" txt_f="11949">We could not detect a significant correlation of UACR with DKK-1, nor with TNF-α. These findings may be explained by our small sample size, and hence the low power of this study to detect such correlations. However, when compared with placebo, GTP therapy significantly reduced DKK-1 and TNF.</offsets></p><p><offsets xml_i="18249" xml_f="18529" txt_i="11950" txt_f="12230">The main limitations of our study and our interpretation of its results are the small sample size and the short duration of the treatment phase. Moreover, in addition to albuminuria, future studies should consider other outcome measures, such as time to renal replacement therapy.</offsets></p><p><offsets xml_i="18536" xml_f="19146" txt_i="12231" txt_f="12841">In conclusion, to our knowledge this is the first randomised, double-blind, placebo-controlled clinical trial to demonstrate the possible efficacy and safety of GTP addition to RAS inhibitors in attenuating residual albuminuria in patients with diabetic nephropathy. This observed efficacy may be due to the capacity of GTP to reduce podocyte apoptosis as a result of reduction of DKK-1. Future multicenter randomized trials with larger samples sizes are necessary to confirm the long-term efficacy and safety of adding GTP to RAS inhibitors with the goal of minimizing the progression of diabetic nephropathy.</offsets></p></sec><sec disp-level="1"><title><offsets xml_i="19183" xml_f="19204" txt_i="12843" txt_f="12864">Materials and Methods</offsets></title><p><offsets xml_i="19215" xml_f="19655" txt_i="12865" txt_f="13305">This randomised, double-blind, placebo-controlled, single-center phase 2 study was conducted in compliance with local and national regulations, Good Clinical Practices guidelines, and Declaration of Helsinki Principles and it was approved by the local Institutional Review Board (Comitê de Ética em Pesquisa, Faculdade de Ciências Médicas, UNICAMP, 18445613.3.0000.5404). All patients signed informed consent before enrollment in the study.</offsets></p><sec disp-level="2"><title><offsets xml_i="19686" xml_f="19694" txt_i="13306" txt_f="13314">Patients</offsets></title><p><offsets xml_i="19705" xml_f="20493" txt_i="13315" txt_f="14100">Eligible patients, identified during routine visits to the Diabetic Nephropathy Clinic at the University Hospital of the State University of Campinas (UNICAMP), were 18 years of age or older, had been previously diagnosed with DM type 1 or 2, and had persistent micro- or macroalbuminuria (UACR over 30 mg/g as determined by three consecutive urine samples obtained on different days) despite treatment with maximum doses of ACE inhibitors and/or ARBs for at least 8 weeks prior to the screening. Included patients also had HbA1c levels &lt;10%, and regularly used insulin and/or oral glucose lowering agents. Exclusion criteria included autoimmune disease, human immunodeficiency virus (HIV) infection, viral hepatitis, neoplasia, pregnancy and lactation, eGFR below 30 mL/min per 1.73 m</offsets><sup><offsets xml_i="20498" xml_f="20499" txt_i="14100" txt_f="14101">2</offsets></sup><offsets xml_i="20505" xml_f="20953" txt_i="14101" txt_f="14549"> as estimated by the CKD Epidemiology Collaboration (CKD-EPI) equation, chronic urinary tract infection, chronic heart failure of New York Heart Association (NYHA) class III or IV, recent history of coronary artery disease, cerebrovascular accidents, history of alcohol dependency or drug abuse, any psychiatric or neurological conditions preventing mindful consent to the study and/or adherence to the study protocol, and intolerance to green tea.</offsets></p></sec><sec disp-level="2"><title><offsets xml_i="20990" xml_f="21020" txt_i="14551" txt_f="14581">Randomization and Study Design</offsets></title><p><offsets xml_i="21031" xml_f="21667" txt_i="14582" txt_f="15218">We screened 370 patients with a diagnosis of diabetes. Of these patients, 47 patients met the inclusion criteria and were randomly assigned to two groups: 24 patients were treated with a maximum dose of ACE inhibitors and/or ARBs plus GTP, and 23 patients were treated with a maximum dose of ACE inhibitors and/or ARBs plus placebo. The patients received either four capsules of GTP (tea polyphenol, TP98, MedKoo Bioscience, Chapel Hill, NC 27516-6222, USA) per day, corresponding to 800 mg of EGCG, or placebo for 12 weeks. The percentage of EGCG, epigallocatechin, and epicatechin present in this GTP was confirmed by our laboratory (</offsets><xref ref-type="supplementary-material" rid="S1"><offsets xml_i="21716" xml_f="21737" txt_i="15218" txt_f="15239">Supplementary Table 1</offsets></xref><offsets xml_i="21744" xml_f="21868" txt_i="15239" txt_f="15363">). The dosage was chosen because it has been shown to be safe and because it might be effective for lowering LDL cholesterol</offsets><xref ref-type="bibr" rid="b16"><offsets xml_i="21900" xml_f="21902" txt_i="15363" txt_f="15365">16</offsets></xref><offsets xml_i="21909" xml_f="22020" txt_i="15365" txt_f="15476">. All drugs and placebo tablets were similar in size, shape, weight, and color. The website Randomization.com (</offsets><ext-link ext-link-type="uri" xlink:href="http://www.randomization.com"><offsets xml_i="22092" xml_f="22120" txt_i="15476" txt_f="15504">http://www.randomization.com</offsets></ext-link><offsets xml_i="22131" xml_f="22604" txt_i="15504" txt_f="15977">) was used to generate the randomization list. All drug and placebo tablets were prepared by Dermage (Campinas, São Paulo, Brazil), and prepacked bottles were numbered for each patient according to the randomization sequence. All clinical investigators, laboratory personnel, and patients were masked to the treatment assignment. To avoid researcher influence, the randomization list was generated and maintained by trained personnel in a different location from the study.</offsets></p></sec><sec disp-level="2"><title><offsets xml_i="22641" xml_f="22664" txt_i="15979" txt_f="16002">Procedures and Outcomes</offsets></title><p><offsets xml_i="22675" xml_f="23212" txt_i="16003" txt_f="16540">Patients were evaluated at baseline and then again after 12 weeks. At these two time points, patients provided three samples of first morning urine to determine albuminuria (primary endpoint) and a complete physical examination was performed, including office and 24-hour blood pressure, and BMI. A fasting blood sample was also obtained for determining secondary endpoints including: eGFR, glycemia, HbA1c, lipid profile, CRP, plasma concentration of DKK-1, TNFα, and urinary 8-isoprostane. Because of our recent preclinical observation</offsets><xref ref-type="bibr" rid="b12"><offsets xml_i="23244" xml_f="23246" txt_i="16540" txt_f="16542">12</offsets></xref><offsets xml_i="23253" xml_f="23715" txt_i="16542" txt_f="17004"> showing the potential of green tea to activate the WNT pathway and to reduce albuminuria under diabetic conditions, we post hoc estimated the plasma concentration of DKK-1, a WNT inhibitor, as a secondary outcome. We also post hoc estimated plasma TNF as a marker of inflammation. Patient adherence to the study was evaluated by monthly phone calls and by tablet counts at the end of the study. Adverse events were assessed during the visits and by phone calls.</offsets></p></sec><sec disp-level="2"><title><offsets xml_i="23752" xml_f="23773" txt_i="17006" txt_f="17027">Laboratory procedures</offsets></title><p><offsets xml_i="23784" xml_f="24741" txt_i="17028" txt_f="17977">Urine samples taken over three consecutive mornings, were used to test for albuminuria at the beginning and the end of the study (Nephelometry, BN II System, Siemens, Germany). Ambulatory blood pressure was monitored over 24 hours (Spacelabs MAPA 90207, Washington, USA) and was measured every 15 minutes during the day and every 30 minutes during the night. Hemoglobin concentration (Sysmex XE-2100, Sysmex Corp., Kobe, Japan), plasma potassium, sodium, creatinine, urea, and lipids (Roche/Hitachi MODULAR P, Roche Lab Systems, Germany) were measured by autoanalyser, CRP was measured by nephelometry (BN ProSpec System, Siemens), and HbA1c was determined using high-performance liquid chromatography (HPLC, Bio-Rad VARIANT II, USA). Plasma DKK1 (R&amp;D, Minneapolis, MN, USA), TNFα (R&amp;D), and urinary 8-isoprostane (ABCAM, Cambridge, MA, USA) were determined using commercially available ELISA kits in accordance with the manufacturer’s instructions.</offsets></p></sec><sec disp-level="2"><title><offsets xml_i="24778" xml_f="24800" txt_i="17979" txt_f="18001">Human podocyte culture</offsets></title><p><offsets xml_i="24811" xml_f="25043" txt_i="18002" txt_f="18234">Conditionally iHPs (M.A. Saleem, Academic Renal Unit, University of Bristol, Southmead Hospital, Bristol, UK) were provided by Luigi Gnudi (King’s College, London, United Kingdom) and were derived and cultured as reported by Saleem </offsets><italic><offsets xml_i="25051" xml_f="25056" txt_i="18234" txt_f="18239">et al</offsets></italic><offsets xml_i="25065" xml_f="25066" txt_i="18239" txt_f="18240">.</offsets><xref ref-type="bibr" rid="b24"><offsets xml_i="25098" xml_f="25100" txt_i="18240" txt_f="18242">24</offsets></xref><offsets xml_i="25107" xml_f="25642" txt_i="18242" txt_f="18777">. Differentiated podocytes cell passage numbers were between 12 and 17, with batches of cells from the same passage number used for each set of experiments. Replicate experiments were performed (the number of experiments is stated in each case below) and representative results are shown. After overnight serum starvation, differentiated cells were exposed to the treatments for the indicated duration. The concentrations of treatments used in all experiments were chosen after carrying out a thiazolyl blue tetrazolium bromide assay (</offsets><xref ref-type="supplementary-material" rid="S1"><offsets xml_i="25691" xml_f="25711" txt_i="18777" txt_f="18797">Supplementary Fig. 1</offsets></xref><offsets xml_i="25718" xml_f="25720" txt_i="18797" txt_f="18799">).</offsets></p></sec><sec disp-level="2"><title><offsets xml_i="25757" xml_f="25782" txt_i="18801" txt_f="18826">Human podocyte treatments</offsets></title><p><offsets xml_i="25793" xml_f="25863" txt_i="18827" txt_f="18897">Starved iHPs were incubated with 4% plasma from each healthy control (</offsets><italic><offsets xml_i="25871" xml_f="25872" txt_i="18897" txt_f="18898">n</offsets></italic><offsets xml_i="25881" xml_f="25969" txt_i="18898" txt_f="18986"> = 3) or from each type 2 diabetic patient treated with GTP, obtained before treatment (</offsets><italic><offsets xml_i="25977" xml_f="25978" txt_i="18986" txt_f="18987">n</offsets></italic><offsets xml_i="25987" xml_f="26034" txt_i="18987" txt_f="19034"> = 3) or after 12 weeks of treatment with GTP (</offsets><italic><offsets xml_i="26042" xml_f="26043" txt_i="19034" txt_f="19035">n</offsets></italic><offsets xml_i="26052" xml_f="26399" txt_i="19035" txt_f="19378"> = 3). Cells were incubated for 6 hours in the presence or absence of a low-density lipoprotein receptor-related protein (LRP) 6 (LRP6) blocker (100 ng/mL DKK-1) (R&amp;D, Minneapolis, MN, USA) or EGCG (436 nM). This concentration of EGCG corresponds to the plasma concentrations obtained after administration of 800 mg of EGCG to healthy controls</offsets><xref ref-type="bibr" rid="b25"><offsets xml_i="26431" xml_f="26433" txt_i="19378" txt_f="19380">25</offsets></xref><offsets xml_i="26440" xml_f="26558" txt_i="19380" txt_f="19498">. These experiments were performed at least twice. Data from the healthy controls and diabetic subjects used in these </offsets><italic><offsets xml_i="26566" xml_f="26574" txt_i="19498" txt_f="19506">in vitro</offsets></italic><offsets xml_i="26583" xml_f="26613" txt_i="19506" txt_f="19536"> experiments are presented in </offsets><xref ref-type="supplementary-material" rid="S1"><offsets xml_i="26662" xml_f="26683" txt_i="19536" txt_f="19557">Supplementary Table 2</offsets></xref><offsets xml_i="26690" xml_f="26773" txt_i="19557" txt_f="19640">. Plasma from diabetic patients and control subjects was obtained at fasting state.</offsets></p></sec><sec disp-level="2"><title><offsets xml_i="26810" xml_f="26834" txt_i="19642" txt_f="19666">Caspase-3 activity assay</offsets></title><p><offsets xml_i="26845" xml_f="26911" txt_i="19667" txt_f="19733">Caspase-3 activity in iHPs was analyzed using a colorimetric assay</offsets><xref ref-type="bibr" rid="b26"><offsets xml_i="26943" xml_f="26945" txt_i="19733" txt_f="19735">26</offsets></xref><offsets xml_i="26952" xml_f="26953" txt_i="19735" txt_f="19736">.</offsets></p></sec><sec disp-level="2"><title><offsets xml_i="26990" xml_f="27001" txt_i="19738" txt_f="19749">TUNEL assay</offsets></title><p><offsets xml_i="27012" xml_f="27354" txt_i="19750" txt_f="20092">The TUNEL method was applied to iHPs using a DeadEnd Fluorometric TUNEL System detection kit (Promega, Madison, WI, USA), according to the manufacturer’s instructions. The quantitative analysis of apoptosis in the cultured podocyte cells was carried out by counting the number of positive cells per total number of cells per square millimeter</offsets><xref ref-type="bibr" rid="b12"><offsets xml_i="27386" xml_f="27388" txt_i="20092" txt_f="20094">12</offsets></xref><offsets xml_i="27395" xml_f="27455" txt_i="20094" txt_f="20154">. Ten microscopic images were evaluated for each individual.</offsets></p></sec><sec disp-level="2"><title><offsets xml_i="27492" xml_f="27512" txt_i="20156" txt_f="20176">Albumin influx assay</offsets></title><p><offsets xml_i="27523" xml_f="27655" txt_i="20177" txt_f="20309">A simple albumin influx assay was used to evaluate the filtration barrier function of the podocyte monolayer as described previously</offsets><xref ref-type="bibr" rid="b12"><offsets xml_i="27687" xml_f="27689" txt_i="20309" txt_f="20311">12</offsets></xref><xref ref-type="bibr" rid="b27"><offsets xml_i="27728" xml_f="27730" txt_i="20311" txt_f="20313">27</offsets></xref><offsets xml_i="27737" xml_f="27765" txt_i="20313" txt_f="20341">. Briefly, podocytes (3 × 10</offsets><sup><offsets xml_i="27770" xml_f="27771" txt_i="20341" txt_f="20342">5</offsets></sup><offsets xml_i="27777" xml_f="28065" txt_i="20342" txt_f="20630">) were seeded onto the collagen-coated transwell filters (3 μm pore; Corning, New York, NY) in the top chamber and cultured under differentiating conditions. After 4 days, podocytes were serum-starved overnight and treated for 6 hours with individual plasma samples from normal subjects (</offsets><italic><offsets xml_i="28073" xml_f="28074" txt_i="20630" txt_f="20631">n</offsets></italic><offsets xml_i="28083" xml_f="28145" txt_i="20631" txt_f="20693"> = 3) and with plasma from the same diabetic patients before (</offsets><italic><offsets xml_i="28153" xml_f="28154" txt_i="20693" txt_f="20694">n</offsets></italic><offsets xml_i="28163" xml_f="28198" txt_i="20694" txt_f="20729"> = 3) or after treatment with GTP (</offsets><italic><offsets xml_i="28206" xml_f="28207" txt_i="20729" txt_f="20730">n</offsets></italic><offsets xml_i="28216" xml_f="28315" txt_i="20730" txt_f="20829"> = 3). Cells were washed twice with phosphate buffered saline (PBS) supplemented with 1 mmol/L MgCl</offsets><sub><offsets xml_i="28320" xml_f="28321" txt_i="20829" txt_f="20830">2</offsets></sub><offsets xml_i="28327" xml_f="28345" txt_i="20830" txt_f="20848"> and 1 mmol/L CaCl</offsets><sub><offsets xml_i="28350" xml_f="28351" txt_i="20848" txt_f="20849">2</offsets></sub><offsets xml_i="28357" xml_f="28771" txt_i="20849" txt_f="21263"> to preserve the cadherin-based junctions. The top chamber was then refilled with 0.5 mL of RPMI 1640 and the bottom chamber with 1 mL of RPMI 1640 supplemented with 40 mg/mL of bovine serum albumin and incubated at 37 °C. A small aliquot of media from the top chamber was collected as a single sample 6 hours later and the albumin concentration was determined using a bicinchoninic acid protein assay kit (Sigma).</offsets></p></sec><sec disp-level="2"><title><offsets xml_i="28808" xml_f="28828" txt_i="21265" txt_f="21285">Statistical analysis</offsets></title><p><offsets xml_i="28839" xml_f="28892" txt_i="21286" txt_f="21339">In accordance with a previous trial of similar design</offsets><xref ref-type="bibr" rid="b28"><offsets xml_i="28924" xml_f="28926" txt_i="21339" txt_f="21341">28</offsets></xref><offsets xml_i="28933" xml_f="29058" txt_i="21341" txt_f="21466">, we calculated that a minimum of 19 patients in each group was necessary to detect a 30% change in UACR (α = 0.05, β = 0.20)</offsets><xref ref-type="bibr" rid="b29"><offsets xml_i="29090" xml_f="29092" txt_i="21466" txt_f="21468">29</offsets></xref><xref ref-type="bibr" rid="b30"><offsets xml_i="29131" xml_f="29133" txt_i="21468" txt_f="21470">30</offsets></xref><offsets xml_i="29140" xml_f="30400" txt_i="21470" txt_f="22730">. Data were analyzed using an intention-to-treat principle, defined as participants who met all of the inclusion criteria, met none of the exclusion criteria, had at least one dose of the study drug, and final laboratory assessment data available for analysis. Clinical parameters are presented as medians and interquartile ranges unless otherwise noted. Exploratory data analysis was performed through summary measures of categorical data and descriptive statistics of quantitative data. To compare categorical clinical variables between groups, the chi-square test was applied and, when necessary, Fisher’s exact test. The Mann–Whitney test was performed for numerical comparison of baseline clinical variables between groups and from baseline to the end of the study. The primary outcome for albuminuria is presented as the geometric mean of % change from baseline and two-sided 95% confidence intervals. The within-group geometric mean change (%) is derived by 100x (exp(LS mean change) −1, and the same transformation is applied on the 95% confidence interval for the geometric mean change (%). For the change from baseline in the urinary albumin-to-creatinine ratio (and associated 95% CI), values were back-transformed to provide GTP-to-placebo ratios. </offsets><italic><offsets xml_i="30408" xml_f="30416" txt_i="22730" txt_f="22738">In vitro</offsets></italic><offsets xml_i="30425" xml_f="30591" txt_i="22738" txt_f="22904"> data presented as mean ± SD were analyzed with a one-way analysis of variance (ANOVA) followed by Bonferroni test. The significance level adopted for this study was </offsets><italic><offsets xml_i="30599" xml_f="30600" txt_i="22904" txt_f="22905">p</offsets></italic><offsets xml_i="30609" xml_f="30778" txt_i="22905" txt_f="23071"> &lt; 0.05. Statistical analyses were conducted using SAS (Statistical Analysis System) software for Windows (version 9.4, SAS Institute Inc., 2002–2008, Cary, NC, USA).</offsets></p></sec></sec><sec disp-level="1"><title><offsets xml_i="30821" xml_f="30843" txt_i="23074" txt_f="23096">Additional Information</offsets></title><p><bold><offsets xml_i="30860" xml_f="30884" txt_i="23097" txt_f="23121">How to cite this article</offsets></bold><offsets xml_i="30891" xml_f="30907" txt_i="23121" txt_f="23137">: Borges, C. M. </offsets><italic><offsets xml_i="30915" xml_f="30920" txt_i="23137" txt_f="23142">et al</offsets></italic><offsets xml_i="30929" xml_f="31065" txt_i="23142" txt_f="23278">. The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: A double-blind randomised clinical trial. </offsets><italic><offsets xml_i="31073" xml_f="31082" txt_i="23278" txt_f="23287">Sci. Rep.</offsets></italic><offsets xml_i="31091" xml_f="31092" txt_i="23287" txt_f="23288">
</offsets><bold><offsets xml_i="31098" xml_f="31099" txt_i="23288" txt_f="23289">6</offsets></bold><offsets xml_i="31106" xml_f="31145" txt_i="23289" txt_f="23328">, 28282; doi: 10.1038/srep28282 (2016).</offsets></p></sec><sec sec-type="supplementary-material" id="S1"><title><offsets xml_i="31209" xml_f="31231" txt_i="23330" txt_f="23352">Supplementary Material</offsets></title><supplementary-material id="d33e23" content-type="local-data"><caption><title><offsets xml_i="31317" xml_f="31340" txt_i="23353" txt_f="23376">Supplementary Dataset 1</offsets></title></caption><media xlink:href="srep28282-s1.doc"></media></supplementary-material></sec></body><back><ack><p></p></ack><ref-list><ref id="b1"><mixed-citation publication-type="journal"><name><surname>Gaede</surname><given-names>P.</given-names></name>, <name><surname>Vedel</surname><given-names>P.</given-names></name>, <name><surname>Parving</surname><given-names>H. H.</given-names></name> &amp; <name><surname>Pedersen</surname><given-names>O.</given-names></name>
<article-title>Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study</article-title>. <source>Lancet</source>
<volume>353</volume>, <fpage>617</fpage>–<lpage>622</lpage> (<year>1999</year>).<pub-id pub-id-type="pmid">10030326</pub-id></mixed-citation></ref><ref id="b2"><mixed-citation publication-type="journal"><name><surname>Tuttle</surname><given-names>K. R.</given-names></name>
<etal></etal>. <article-title>Diabetic kidney disease: a report from ADA Consensus Conference</article-title>. <source>Diabetes Care</source>
<volume>37</volume>, <fpage>2864</fpage>–<lpage>2883</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25249672</pub-id></mixed-citation></ref><ref id="b3"><mixed-citation publication-type="journal"><name><surname>De Zeeuw</surname><given-names>D.</given-names></name>
<etal></etal>. <article-title>Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy</article-title>. <source>Circulation</source>
<volume>110</volume>, <fpage>921</fpage>–<lpage>927</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15302780</pub-id></mixed-citation></ref><ref id="b4"><mixed-citation publication-type="journal"><name><surname>Holtkamp</surname><given-names>F. A.</given-names></name>
<etal></etal>. <article-title>Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy</article-title>. <source>Eur. Heart J.</source>
<volume>32</volume>, <fpage>1493</fpage>–<lpage>1499</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21421598</pub-id></mixed-citation></ref><ref id="b5"><mixed-citation publication-type="journal"><name><surname>Ninomiya</surname><given-names>T.</given-names></name>
<etal></etal>. <article-title>Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes</article-title>. <source>J. Am. Soc. Nephrol.</source>
<volume>20</volume>, <fpage>1813</fpage>–<lpage>1821</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19443635</pub-id></mixed-citation></ref><ref id="b6"><mixed-citation publication-type="journal"><name><surname>Schmeider</surname><given-names>R. E.</given-names></name>
<etal></etal>. <article-title>Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure</article-title>. <source>Diabetologia</source>
<volume>57</volume>, <fpage>2019</fpage>–<lpage>2029</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25037746</pub-id></mixed-citation></ref><ref id="b7"><mixed-citation publication-type="journal"><name><surname>Bakris</surname><given-names>G. L.</given-names></name>
<article-title>Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus</article-title>. <source>Mayo Clin. Proc.</source>
<volume>86</volume>, <fpage>444</fpage>–<lpage>456</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21531886</pub-id></mixed-citation></ref><ref id="b8"><mixed-citation publication-type="journal"><name><surname>Yamout</surname><given-names>H.</given-names></name>, <name><surname>Lazich</surname><given-names>I.</given-names></name> &amp; <name><surname>Bakris</surname><given-names>G. L.</given-names></name>
<article-title>Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease</article-title>. <source>Adv. Chronic. Kidney Dis.</source>
<volume>21</volume>, <fpage>281</fpage>–<lpage>286</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24780456</pub-id></mixed-citation></ref><ref id="b9"><mixed-citation publication-type="journal"><name><surname>De Zeeuw</surname><given-names>D.</given-names></name>
<etal></etal>. <article-title>Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL</article-title>. <source>Kidney Int.</source>
<volume>65</volume>, <fpage>2309</fpage>–<lpage>2320</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15149345</pub-id></mixed-citation></ref><ref id="b10"><mixed-citation publication-type="journal"><name><surname>Ribaldo</surname><given-names>P. D. B.</given-names></name>
<etal></etal>. <article-title>Green tea (Camellia sinensis) attenuates nephropathy by downregulating Nox4 NADPH oxidase in diabetic spontaneously hypertensive rats</article-title>. <source>J. Nutr.</source>
<volume>139</volume>, <fpage>96</fpage>–<lpage>100</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19056645</pub-id></mixed-citation></ref><ref id="b11"><mixed-citation publication-type="journal"><name><surname>Faria</surname><given-names>A. M.</given-names></name>, <name><surname>Papadimitriou</surname><given-names>A.</given-names></name>, <name><surname>Silva</surname><given-names>K. C.</given-names></name>, <name><surname>Lopes de Faria</surname><given-names>J. M.</given-names></name> &amp; <name><surname>Lopes de Faria</surname><given-names>J. B.</given-names></name>
<article-title>Uncoupling endothelial nitric oxide synthase is ameliorated by green tea in experimental diabetes by re-establishing tetrahydrobiopterin levels</article-title>. <source>Diabetes</source>
<volume>61</volume>, <fpage>1838</fpage>–<lpage>1847</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22586583</pub-id></mixed-citation></ref><ref id="b12"><mixed-citation publication-type="journal"><name><surname>Peixoto</surname><given-names>E. B.</given-names></name>
<etal></etal>. <article-title>Reduced LRP6 expression and increase in the interaction of GSK3β with p53 contribute to podocyte apoptosis in diabetes mellitus and are prevented by green tea</article-title>. <source>J. Nutr. Biochem.</source>
<volume>4</volume>, <fpage>416</fpage>–<lpage>430</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25655048</pub-id></mixed-citation></ref><ref id="b13"><mixed-citation publication-type="journal"><name><surname>Peng</surname><given-names>A.</given-names></name>
<etal></etal>. <article-title>The green tea polyphenol (−)-epigallocatechin-3-gallate ameliorates experimental immune-mediated glomerulonephritis</article-title>. <source>Kidney Int.</source>
<volume>80</volume>, <fpage>601</fpage>–<lpage>611</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21544063</pub-id></mixed-citation></ref><ref id="b14"><mixed-citation publication-type="journal"><name><surname>Kato</surname><given-names>H.</given-names></name>
<etal></etal>. <article-title>Wnt/b-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival</article-title>. <source>J. Biol. Chem.</source>
<volume>286</volume>, <fpage>26003</fpage>–<lpage>26015</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21613219</pub-id></mixed-citation></ref><ref id="b15"><mixed-citation publication-type="journal"><name><surname>Ras</surname><given-names>R. T.</given-names></name>, <name><surname>Zock</surname><given-names>P. L.</given-names></name> &amp; <name><surname>Draijer</surname><given-names>R.</given-names></name>
<article-title>Tea consumption enhances endothelial-dependent vasodilation: a meta-analysis</article-title>. <source>PLoS One</source>
<volume>6</volume>, <fpage>e16974</fpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21394199</pub-id></mixed-citation></ref><ref id="b16"><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>A. H.</given-names></name>
<etal></etal>. <article-title>Effect of 2-month controlled green tea intervention on lipoprotein cholesterol, glucose, and hormone levels in healthy postmenopausal women</article-title>. <source>Cancer Prev. Res.</source>
<volume>5</volume>, <fpage>393</fpage>–<lpage>402</lpage> (<year>2012</year>).</mixed-citation></ref><ref id="b17"><mixed-citation publication-type="journal"><name><surname>Navarro-González</surname><given-names>J. F.</given-names></name> &amp; <name><surname>Mora-Fernández</surname><given-names>C.</given-names></name>
<article-title>The role of inflammatory cytokines in diabetic nephropathy</article-title>. <source>J. Am. Soc. Nephrol.</source>
<volume>19</volume>, <fpage>433</fpage>–<lpage>442</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18256353</pub-id></mixed-citation></ref><ref id="b18"><mixed-citation publication-type="journal"><name><surname>Garcia-Martín</surname><given-names>A.</given-names></name>
<etal></etal>. <article-title>Relationship of Dickkopf1 (DKK1) with cardiovascular disease and bone metabolism in Caucasian type 2 diabetes mellitus</article-title>. <source>PLoS One</source>
<volume>9</volume>, <fpage>e111703</fpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25369286</pub-id></mixed-citation></ref><ref id="b19"><mixed-citation publication-type="journal"><name><surname>Lattanzio</surname><given-names>S.</given-names></name>
<etal></etal>. <article-title>Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin</article-title>. <source>J. Am. Heart Assoc.</source>
<volume>3</volume>, <fpage>3</fpage>–<lpage>11</lpage> (<year>2014</year>).</mixed-citation></ref><ref id="b20"><mixed-citation publication-type="journal"><name><surname>Bafico</surname><given-names>A.</given-names></name>, <name><surname>Liu</surname><given-names>G.</given-names></name>, <name><surname>Yaniv</surname><given-names>A.</given-names></name>, <name><surname>Gazit</surname><given-names>A.</given-names></name> &amp; <name><surname>Aaronson</surname><given-names>S. A.</given-names></name>
<article-title>Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP-6</article-title>. <source>Nat. Cell Biol.</source>
<volume>3</volume>, <fpage>683</fpage>–<lpage>686</lpage> (<year>2001</year>).<pub-id pub-id-type="pmid">11433302</pub-id></mixed-citation></ref><ref id="b21"><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>Z.</given-names></name>, <name><surname>Xu</surname><given-names>J.</given-names></name>, <name><surname>Xu</surname><given-names>P.</given-names></name>, <name><surname>Liu</surname><given-names>S.</given-names></name> &amp; <name><surname>Yang</surname><given-names>Z.</given-names></name>
<article-title>Wnt/β-catenin signalling pathway mediates high glucose induced cell injury through activation of TRPC6 in podocytes</article-title>. <source>Cell Prolif.</source>
<volume>46</volume>, <fpage>76</fpage>–<lpage>85</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23294354</pub-id></mixed-citation></ref><ref id="b22"><mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>P.</given-names></name> &amp; <name><surname>Frame</surname><given-names>S.</given-names></name>
<article-title>The renaissance of GSK3</article-title>. <source>Mol. Cell Biol.</source>
<volume>2</volume>, <fpage>769</fpage>–<lpage>76</lpage> (<year>2001</year>).</mixed-citation></ref><ref id="b23"><mixed-citation publication-type="journal"><name><surname>Merscher-Gomez</surname><given-names>S.</given-names></name>
<etal></etal>. <article-title>Cyclodextrin protects podocytes in diabetic kidney disease</article-title>. <source>Diabetes</source>
<volume>62</volume>, <fpage>3817</fpage>–<lpage>3827</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23835338</pub-id></mixed-citation></ref><ref id="b24"><mixed-citation publication-type="journal"><name><surname>Saleem</surname><given-names>M. A.</given-names></name>
<etal></etal>. <article-title>A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression</article-title>. <source>J. Am. Soc. Nephrol.</source>
<volume>13</volume>, <fpage>630</fpage>–<lpage>638</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">11856766</pub-id></mixed-citation></ref><ref id="b25"><mixed-citation publication-type="journal"><name><surname>Chow</surname><given-names>H. H.</given-names></name>
<etal></etal>. <article-title>Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of polyphenon E in healthy individuals</article-title>. <source>Clin. Cancer Res.</source>
<volume>12</volume>, <fpage>4627</fpage>–<lpage>4633</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15958649</pub-id></mixed-citation></ref><ref id="b26"><mixed-citation publication-type="journal"><name><surname>Papadimitriou</surname><given-names>A.</given-names></name>, <name><surname>King</surname><given-names>A. J.</given-names></name>, <name><surname>Jones</surname><given-names>P. M.</given-names></name> &amp; <name><surname>Persaud</surname><given-names>S. J.</given-names></name>
<article-title>Anti-apoptotic effects of arachidonic acid and prostaglandin E2 in pancreatic beta-cells</article-title>. <source>Cell Physiol. Biochem.</source>
<volume>20</volume>, <fpage>607</fpage>–<lpage>616</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17762187</pub-id></mixed-citation></ref><ref id="b27"><mixed-citation publication-type="journal"><name><surname>Fang</surname><given-names>L.</given-names></name>
<etal></etal>. <article-title>Autophagy attenuates diabetic glomerular damage through protection of hyperglycemia-induced podocyte injury</article-title>. <source>PLoS One</source>
<volume>8</volume>, <fpage>e60546</fpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23593240</pub-id></mixed-citation></ref><ref id="b28"><mixed-citation publication-type="journal"><name><surname>Schjoedt</surname><given-names>K. J.</given-names></name>
<etal></etal>. <article-title>Benefical impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy</article-title>. <source>Kidney Int.</source>
<volume>70</volume>, <fpage>536</fpage>–<lpage>542</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16775595</pub-id></mixed-citation></ref><ref id="b29"><mixed-citation publication-type="journal"><name><surname>Fleiss</surname><given-names>J. L.</given-names></name>, <name><surname>Levin</surname><given-names>B.</given-names></name> &amp; <name><surname>Paik</surname><given-names>M. C.</given-names></name>
<source>Statistical Methods for Rates and Proportions.</source> 2nd ed. (John Wiley &amp; Sons, <year>1981</year>).</mixed-citation></ref><ref id="b30"><mixed-citation publication-type="journal"><name><surname>Hulley</surname><given-names>S. B.</given-names></name>, <name><surname>Cummings</surname><given-names>S. R.</given-names></name>, <name><surname>Browner</surname><given-names>W. S.</given-names></name>, <name><surname>Grady</surname><given-names>D. G.</given-names></name> &amp; <name><surname>Newman</surname><given-names>T. B.</given-names></name>
<article-title>Designing</article-title>
<source>Clinical Research.</source> 4th ed. (Williams &amp; Wilkins, <year>2013</year>).</mixed-citation></ref></ref-list><fn-group><fn><p><bold>Author Contributions</bold> C.M.B. acquired data, drafted the manuscript, and approved the final version. A.P. acquired data, revised the manuscript, and approved the final version. D.A.D. acquired data, revised the manuscript, and approved the final version. J.M.L.d.F. played an important role in interpreting the results, revised the manuscript, and approved the final version. J.B.L.F. conceived and designed the work that led to this submission, interpreted the results, revised the manuscript, and approved the final version.</p></fn></fn-group></back><floats-group><fig id="f1"><label>Figure 1</label><caption><title>Flow diagram of the trial.</title><p>eGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus; NYHA, New York Heart Association; HbA1c, glycated hemoglobin; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.</p></caption><graphic xlink:href="srep28282-f1"></graphic></fig><fig id="f2"><label>Figure 2</label><caption><title>Patients in the green tea polyphenol group (n = 21) experienced a significant reduction in UACR, while patients in the placebo (n = 21) group experienced a small increase.</title><p>Geometric mean of % change in urinary albumin-creatinine ratio from baseline to the end of the study. Vertical bars represent the 95% confidence intervals. <italic>P</italic> value is for comparison between the green tea polyphenol and the placebo groups.</p></caption><graphic xlink:href="srep28282-f2"></graphic></fig><fig id="f3"><label>Figure 3</label><caption><title>Analysis of the filtration barrier function of the podocyte monolayer by an albumin efflux assay.</title><p>Differentiated iHPs were incubated with plasma from each healthy controls (n = 3) and plasma from each diabetic subjects before (n = 3) or after 12 weeks treatment with GTP (n = 3) and albumin influx through podocyte monolayer was assessed after 6 hours, as described in methods. Data are presented as mean and vertical bars represent the standard deviation. *<italic>P</italic> &lt; 0.001 vs. control, <sup>#</sup><italic>P</italic> = 0.003 vs. diabetic, <sup>$</sup><italic>P</italic> &lt; 0.001 vs. diabetic GTP, <sup>&amp;</sup><italic>P</italic> = 0.01 vs. diabetic. GTP, green tea polyphenol; DKK-1, dickkopf 1, EGCG, epigallocatechin gallate.</p></caption><graphic xlink:href="srep28282-f3"></graphic></fig><fig id="f4"><label>Figure 4</label><caption><title>Analysis of podocyte apoptosis.</title><p>(<bold>A,B</bold>) TUNEL assay, scale bars 50 μm. Bars in B represent the median of three human plasma samples derived from an average of ten fields. Vertical bars represent the standard deviation. <italic>N</italic> = 3 for each condition. *<italic>P</italic> = 0.01 vs. control, <sup>#</sup><italic>P</italic> = 0.01 vs. diabetic, <sup>$</sup><italic>P</italic> &lt; 0.001 vs. diabetic GTP, <sup>&amp;</sup><italic>P</italic> &lt; 0.001 vs. diabetic. (<bold>C</bold>) Caspase-3 activity. Data are presented as mean ± SD; <italic>N</italic> = 3 for each condition. *<italic>P</italic> &lt; 0.001 vs. control, <sup>#</sup><italic>P</italic> &lt; 0.001 vs. diabetic, <sup>$</sup><italic>P</italic> &lt; 0.001 vs. diabetic GTP, <sup>&amp;</sup><italic>P</italic> = 0.007 vs. diabetic. GTP, green tea polyphenol; DKK-1, dickkopf 1, EGCG, epigallocatechin gallate.</p></caption><graphic xlink:href="srep28282-f4"></graphic></fig><table-wrap position="float" id="t1"><label>Table 1</label><caption><title>Baseline characteristics of patients<xref ref-type="fn" rid="t1-fn1">^</xref>.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">Characteristic</th><th align="center" valign="top" charoff="50">Green tea polyphenol (<italic>N</italic> = 23)</th><th align="center" valign="top" charoff="50">Placebo (<italic>N</italic> = 24)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Age–yr</td><td align="center" valign="top" charoff="50">63 (60–65)</td><td align="center" valign="top" charoff="50">59 (49–63)</td></tr><tr><td align="left" valign="top" charoff="50">Male sex–no. (%)</td><td align="center" valign="top" charoff="50">11 (47.8)</td><td align="center" valign="top" charoff="50">16 (66.7)</td></tr><tr><td align="left" valign="top" charoff="50">DM type 2–no. (%)</td><td align="center" valign="top" charoff="50">23 (100)</td><td align="center" valign="top" charoff="50">19 (79)</td></tr><tr><td align="left" valign="top" charoff="50">Known duration of DM–yr</td><td align="center" valign="top" charoff="50">16 (12–20)</td><td align="center" valign="top" charoff="50">19 (13–22)</td></tr><tr><td align="left" valign="top" charoff="50">Use of insulin–no. (%)</td><td align="center" valign="top" charoff="50">17 (73.9)</td><td align="center" valign="top" charoff="50">19 (79.2)</td></tr><tr><td align="left" valign="top" charoff="50">Use of statins–no. (%)</td><td align="center" valign="top" charoff="50">19 (82.6)</td><td align="center" valign="top" charoff="50">22 (91.7)</td></tr><tr><td align="left" valign="top" charoff="50">Use of aspirin–no. (%)</td><td align="center" valign="top" charoff="50">17 (73.9)</td><td align="center" valign="top" charoff="50">17 (70.8)</td></tr><tr><td align="left" valign="top" charoff="50">Body-mass index–kg/m<sup>2</sup></td><td align="center" valign="top" charoff="50">30.6 (27.5–34.7)</td><td align="center" valign="top" charoff="50">32.7 (28.6–35.5)</td></tr><tr><td align="left" valign="top" charoff="50">Waist circumference–cm</td><td align="center" valign="top" charoff="50">107 (99–113)</td><td align="center" valign="top" charoff="50">114 (99–119)</td></tr><tr><td align="left" valign="top" charoff="50">Diabetic retinopathy–no. (%)</td><td align="center" valign="top" charoff="50">19 (82.6)</td><td align="center" valign="top" charoff="50">17 (70.8)</td></tr><tr><td align="left" valign="top" charoff="50">ACEi/ARB/ACEi+ARB–no.</td><td align="center" valign="top" charoff="50">10/12/1</td><td align="center" valign="top" charoff="50">7/14/3</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50">Systolic blood pressure–mmHg</td></tr><tr><td align="left" valign="top" charoff="50"> Office</td><td align="center" valign="top" charoff="50">151 (140–159)</td><td align="center" valign="top" charoff="50">140 (131–160)</td></tr><tr><td align="left" valign="top" charoff="50"> 24 hour</td><td align="center" valign="top" charoff="50">140 (128–144)</td><td align="center" valign="top" charoff="50">132 (118–139)</td></tr><tr><td colspan="3" align="left" valign="top" charoff="50">Diastolic blood pressure–mmHg</td></tr><tr><td align="left" valign="top" charoff="50"> Office</td><td align="center" valign="top" charoff="50">89 (81–97)</td><td align="center" valign="top" charoff="50">84 (76–99)</td></tr><tr><td align="left" valign="top" charoff="50"> 24 hour</td><td align="center" valign="top" charoff="50">76 (70–82)</td><td align="center" valign="top" charoff="50">73 (69–79)</td></tr><tr><td align="left" valign="top" charoff="50">Fasting plasma glucose–mg/dL</td><td align="center" valign="top" charoff="50">136 (118–180)</td><td align="center" valign="top" charoff="50">143 (99–194)</td></tr><tr><td align="left" valign="top" charoff="50">Glycated hemoglobin–%</td><td align="center" valign="top" charoff="50">7.7 (7.3–8.3)</td><td align="center" valign="top" charoff="50">8.2 (7.5–9.2)</td></tr><tr><td align="left" valign="top" charoff="50">Serum triglycerides–mg/dL</td><td align="center" valign="top" charoff="50">163 (110–195)</td><td align="center" valign="top" charoff="50">144 (97–207)</td></tr><tr><td align="left" valign="top" charoff="50">Serum total cholesterol–mg/dL</td><td align="center" valign="top" charoff="50">157 (136–169)</td><td align="center" valign="top" charoff="50">156 (147–186)</td></tr><tr><td align="left" valign="top" charoff="50">Serum LDL-C–mg/dL</td><td align="center" valign="top" charoff="50">84 (68–90)</td><td align="center" valign="top" charoff="50">86 (69–91)</td></tr><tr><td align="left" valign="top" charoff="50">Serum HDL-C–mg/dL</td><td align="center" valign="top" charoff="50">40 (33–46)</td><td align="center" valign="top" charoff="50">42 (36–51)</td></tr><tr><td align="left" valign="top" charoff="50">Serum CRP–mg/dL</td><td align="center" valign="top" charoff="50">0.40 (0.08–0.72)</td><td align="center" valign="top" charoff="50">0.23 (0.08–0.47)</td></tr><tr><td align="left" valign="top" charoff="50">eGFR–mL/min per 1.73 m<sup>2</sup><xref ref-type="fn" rid="t1-fn2">#</xref></td><td align="center" valign="top" charoff="50">55.7 (44.3–71.7)</td><td align="center" valign="top" charoff="50">65.6 (46.2–85.6)</td></tr><tr><td align="left" valign="top" charoff="50">UACR–mg/g<xref ref-type="fn" rid="t1-fn3">&amp;</xref></td><td align="center" valign="top" charoff="50">210 (39–1267)</td><td align="center" valign="top" charoff="50">427 (77–4051)</td></tr><tr><td align="left" valign="top" charoff="50">Micro/Macroalbuminuria–no. (%)<xref ref-type="fn" rid="t1-fn4">¶</xref></td><td align="center" valign="top" charoff="50">16 (70)/7 (30)</td><td align="center" valign="top" charoff="50">10 (42)/14 (58)</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviations: DM, diabetes mellitus; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; LDL, low-density lipoprotein; HDL, high-density lipoprotein; CRP, C-reactive protein; UACR, urinary albumin-to-creatinine ratio.</p></fn><fn id="t1-fn2"><p><sup>^</sup>Values are median and interquartile ranges unless otherwise noted.</p></fn><fn id="t1-fn3"><p><sup>#</sup>The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration formula.</p></fn><fn id="t1-fn4"><p><sup>&amp;</sup>Values are median (range).</p></fn><fn id="t1-fn5"><p><sup>¶</sup>Microalbuminuria, UACR = 30–300 mg/g; macroalbuminuria, UACR &gt;300 mg/g.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t2"><label>Table 2</label><caption><title>Change from baseline in the two groups.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="center" valign="top" charoff="50"> </th><th align="center" valign="top" charoff="50">GTP (<italic>N</italic> = 21)</th><th align="center" valign="top" charoff="50">Placebo (<italic>N</italic> = 21)</th><th align="center" valign="top" charoff="50"><italic>P</italic> value between groups</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Δ 24-hour systolic BP–mmHg</td><td align="center" valign="top" charoff="50">−0.02 (−0.03/0.01)</td><td align="center" valign="top" charoff="50">−0.02 (−0.08/0.04)</td><td align="center" valign="top" charoff="50">0.62</td></tr><tr><td align="left" valign="top" charoff="50">Δ 24-hour diastolic BP–mmHg</td><td align="center" valign="top" charoff="50">−0.01 (−0.06/0.05)</td><td align="center" valign="top" charoff="50">0.01 (−0.02/0.08)</td><td align="center" valign="top" charoff="50">0.35</td></tr><tr><td align="left" valign="top" charoff="50">BMI–kg/m<sup>2</sup></td><td align="center" valign="top" charoff="50">0.01 (0.00/0.02)</td><td align="center" valign="top" charoff="50">0.00 (−0.01/0.01)</td><td align="center" valign="top" charoff="50">0.32</td></tr><tr><td align="left" valign="top" charoff="50">HbA1c–%</td><td align="center" valign="top" charoff="50">0.01 (−0.06/0.07)</td><td align="center" valign="top" charoff="50">0.02 (−0.04/0.05)</td><td align="center" valign="top" charoff="50">0.86</td></tr><tr><td align="left" valign="top" charoff="50">CRP–mg/dL</td><td align="center" valign="top" charoff="50">0.15 (−0.30/0.40)</td><td align="center" valign="top" charoff="50">0.00 (−0.28/0.60)</td><td align="center" valign="top" charoff="50">0.29</td></tr><tr><td align="left" valign="top" charoff="50">eGFR–mL/min per 1.73 m<sup>2#</sup></td><td align="center" valign="top" charoff="50">−0.07 (−0.18/0.02)</td><td align="center" valign="top" charoff="50">−0.01 (−0.13/0.09)</td><td align="center" valign="top" charoff="50">0.42</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>Data are expressed as median of percentage change between the two evaluation points, baseline and 12 weeks (interquartile range).</p></fn><fn id="t2-fn2"><p><sup>#</sup>The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration formula.</p></fn><fn id="t2-fn3"><p>Abbreviations: GTP, green tea polyphenol; BP, blood pressure; BMI, body-mass index; HbA1c, glycated hemoglobin; CRP, C-reactive protein.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t3"><label>Table 3</label><caption><title>Median and change from baseline of the two groups.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"></col><col align="center"></col><col align="center"></col><col align="center"></col></colgroup><thead valign="bottom"><tr><th align="center" valign="top" charoff="50"> </th><th align="center" valign="top" charoff="50">GTP</th><th align="center" valign="top" charoff="50">Placebo</th><th align="center" valign="top" charoff="50"><italic>P</italic> Value between groups</th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" charoff="50"><bold>DKK-1 (pg/mL)</bold></td></tr><tr><td align="left" valign="top" charoff="50">Median baseline (IQR)</td><td align="center" valign="top" charoff="50">787 (631/948)</td><td align="center" valign="top" charoff="50">839 (495/1063)</td><td align="center" valign="top" charoff="50">0.84</td></tr><tr><td align="left" valign="top" charoff="50">Δ Median after 12 weeks (IQR)</td><td align="center" valign="top" charoff="50">−0.39 (−0.62/−0.26)</td><td align="center" valign="top" charoff="50">0.01 (−0.05/0.13)</td><td align="center" valign="top" charoff="50">&lt;0.001</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><bold>TNF-α (pg/mL)</bold></td></tr><tr><td align="left" valign="top" charoff="50">Median baseline (IQR)</td><td align="center" valign="top" charoff="50">13.5 (11.3/17.5)</td><td align="center" valign="top" charoff="50">14.5 (11.8/15.1)</td><td align="center" valign="top" charoff="50">0.82</td></tr><tr><td align="left" valign="top" charoff="50">Δ Median after 12 weeks (IQR)</td><td align="center" valign="top" charoff="50">−0.16 (−0.28/−0.06)</td><td align="center" valign="top" charoff="50">0.06 (−0.03/0.15)</td><td align="center" valign="top" charoff="50">&lt;0.001</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50"><bold>8-isoprostane levels (fg/mg creatinine)</bold></td></tr><tr><td align="left" valign="top" charoff="50">Median baseline (IQR)</td><td align="center" valign="top" charoff="50">8.9 (7.1/2.5)</td><td align="center" valign="top" charoff="50">7.5 (4.5/15.6)</td><td align="center" valign="top" charoff="50">0.60</td></tr><tr><td align="left" valign="top" charoff="50">Δ Median after 12 weeks (IQR)</td><td align="center" valign="top" charoff="50">0.09 (−0.12/0.42)</td><td align="center" valign="top" charoff="50">0.05 (−0.06/0.33)</td><td align="center" valign="top" charoff="50">0.87</td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><p>Abbreviations: GTP, green tea polyphenol; DKK-1, Dickkopf WNT pathway inhibitor 1; TNF-α, tumor necrosis factor alpha.</p></fn></table-wrap-foot></table-wrap></floats-group></article>